dr. reddy's labs glp-1 receptor agonist medications Laboratories Launches Obeda: A Breakthrough in Type 2 Diabetes Treatment, ETPharma Dr. Reddy's to expand GLP-1

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection

Pharmacy M explores oral tablets, injections, side effects, and practical UK options for 2026.

Other adverse effects, including depression, sleep disturbances, and anxiety, have also been noted.While these side effects are usually transient, they can be bothersome enough to prompt some patients to discontinue treatment prematurely

If you're on medications or managing a health condition, check with your provider before use

Semaglutide: Tirzepatide is a dual agonist for GLP-1 and GIP receptors

The Latin America Glucagon-like Peptide-1 (GLP-1) Agonists Market worth USD 2.91 billion in 2026 is growing at a CAGR of 8.24% to reach USD 4.33 billion by 2031